Cargando…

Diarylureas: Repositioning from Antitumor to Antimicrobials or Multi-Target Agents against New Pandemics

Antimicrobials have allowed medical advancements over several decades. However, the continuous emergence of antimicrobial resistance restricts efficacy in treating infectious diseases. In this context, the drug repositioning of already known biological active compounds to antimicrobials could repres...

Descripción completa

Detalles Bibliográficos
Autores principales: Catalano, Alessia, Iacopetta, Domenico, Pellegrino, Michele, Aquaro, Stefano, Franchini, Carlo, Sinicropi, Maria Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833385/
https://www.ncbi.nlm.nih.gov/pubmed/33477901
http://dx.doi.org/10.3390/antibiotics10010092
_version_ 1783642053201100800
author Catalano, Alessia
Iacopetta, Domenico
Pellegrino, Michele
Aquaro, Stefano
Franchini, Carlo
Sinicropi, Maria Stefania
author_facet Catalano, Alessia
Iacopetta, Domenico
Pellegrino, Michele
Aquaro, Stefano
Franchini, Carlo
Sinicropi, Maria Stefania
author_sort Catalano, Alessia
collection PubMed
description Antimicrobials have allowed medical advancements over several decades. However, the continuous emergence of antimicrobial resistance restricts efficacy in treating infectious diseases. In this context, the drug repositioning of already known biological active compounds to antimicrobials could represent a useful strategy. In 2002 and 2003, the SARS-CoV pandemic immobilized the Far East regions. However, the drug discovery attempts to study the virus have stopped after the crisis declined. Today’s COVID-19 pandemic could probably have been avoided if those efforts against SARS-CoV had continued. Recently, a new coronavirus variant was identified in the UK. Because of this, the search for safe and potent antimicrobials and antivirals is urgent. Apart from antiviral treatment for severe cases of COVID-19, many patients with mild disease without pneumonia or moderate disease with pneumonia have received different classes of antibiotics. Diarylureas are tyrosine kinase inhibitors well known in the art as anticancer agents, which might be useful tools for a reposition as antimicrobials. The first to come onto the market as anticancer was sorafenib, followed by some other active molecules. For this interesting class of organic compounds antimicrobial, antiviral, antithrombotic, antimalarial, and anti-inflammatory properties have been reported in the literature. These numerous properties make these compounds interesting for a new possible pandemic considering that, as well as for other viral infections also for CoVID-19, a multitarget therapeutic strategy could be favorable. This review is meant to be an overview on diarylureas, focusing on their biological activities, not dwelling on the already known antitumor activity. Quite a lot of papers present in the literature underline and highlight the importance of these molecules as versatile scaffolds for the development of new and promising antimicrobials and multitarget agents against new pandemic events.
format Online
Article
Text
id pubmed-7833385
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78333852021-01-26 Diarylureas: Repositioning from Antitumor to Antimicrobials or Multi-Target Agents against New Pandemics Catalano, Alessia Iacopetta, Domenico Pellegrino, Michele Aquaro, Stefano Franchini, Carlo Sinicropi, Maria Stefania Antibiotics (Basel) Review Antimicrobials have allowed medical advancements over several decades. However, the continuous emergence of antimicrobial resistance restricts efficacy in treating infectious diseases. In this context, the drug repositioning of already known biological active compounds to antimicrobials could represent a useful strategy. In 2002 and 2003, the SARS-CoV pandemic immobilized the Far East regions. However, the drug discovery attempts to study the virus have stopped after the crisis declined. Today’s COVID-19 pandemic could probably have been avoided if those efforts against SARS-CoV had continued. Recently, a new coronavirus variant was identified in the UK. Because of this, the search for safe and potent antimicrobials and antivirals is urgent. Apart from antiviral treatment for severe cases of COVID-19, many patients with mild disease without pneumonia or moderate disease with pneumonia have received different classes of antibiotics. Diarylureas are tyrosine kinase inhibitors well known in the art as anticancer agents, which might be useful tools for a reposition as antimicrobials. The first to come onto the market as anticancer was sorafenib, followed by some other active molecules. For this interesting class of organic compounds antimicrobial, antiviral, antithrombotic, antimalarial, and anti-inflammatory properties have been reported in the literature. These numerous properties make these compounds interesting for a new possible pandemic considering that, as well as for other viral infections also for CoVID-19, a multitarget therapeutic strategy could be favorable. This review is meant to be an overview on diarylureas, focusing on their biological activities, not dwelling on the already known antitumor activity. Quite a lot of papers present in the literature underline and highlight the importance of these molecules as versatile scaffolds for the development of new and promising antimicrobials and multitarget agents against new pandemic events. MDPI 2021-01-19 /pmc/articles/PMC7833385/ /pubmed/33477901 http://dx.doi.org/10.3390/antibiotics10010092 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Catalano, Alessia
Iacopetta, Domenico
Pellegrino, Michele
Aquaro, Stefano
Franchini, Carlo
Sinicropi, Maria Stefania
Diarylureas: Repositioning from Antitumor to Antimicrobials or Multi-Target Agents against New Pandemics
title Diarylureas: Repositioning from Antitumor to Antimicrobials or Multi-Target Agents against New Pandemics
title_full Diarylureas: Repositioning from Antitumor to Antimicrobials or Multi-Target Agents against New Pandemics
title_fullStr Diarylureas: Repositioning from Antitumor to Antimicrobials or Multi-Target Agents against New Pandemics
title_full_unstemmed Diarylureas: Repositioning from Antitumor to Antimicrobials or Multi-Target Agents against New Pandemics
title_short Diarylureas: Repositioning from Antitumor to Antimicrobials or Multi-Target Agents against New Pandemics
title_sort diarylureas: repositioning from antitumor to antimicrobials or multi-target agents against new pandemics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833385/
https://www.ncbi.nlm.nih.gov/pubmed/33477901
http://dx.doi.org/10.3390/antibiotics10010092
work_keys_str_mv AT catalanoalessia diarylureasrepositioningfromantitumortoantimicrobialsormultitargetagentsagainstnewpandemics
AT iacopettadomenico diarylureasrepositioningfromantitumortoantimicrobialsormultitargetagentsagainstnewpandemics
AT pellegrinomichele diarylureasrepositioningfromantitumortoantimicrobialsormultitargetagentsagainstnewpandemics
AT aquarostefano diarylureasrepositioningfromantitumortoantimicrobialsormultitargetagentsagainstnewpandemics
AT franchinicarlo diarylureasrepositioningfromantitumortoantimicrobialsormultitargetagentsagainstnewpandemics
AT sinicropimariastefania diarylureasrepositioningfromantitumortoantimicrobialsormultitargetagentsagainstnewpandemics